SURVYR

CDNA

CareDx, Inc.
$72.13
+$1.60 (2.27%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-7%+95%+197%+299%+401%Oct 2025Oct 2026Apr 202652w high $72.7152w low $14.22
CDNASPY
Wall St. Highest PT $80.00 (+10.9%) Wall St. Avg PT $64.17 (-11.0%)
$14$31$48$65$82POC $20Hi $80Avg $64
Underwater Drawdown %Max DD -23.6%Current 0.0%
0.0%-23.6%
Relative Strength vs SPY+383.2% vs SPYOutperforming
+441%0%-441%
1W
+$1.39 (1.96%)
1M
+$7.53 (11.66%)
3M
+$36.72 (103.70%)
6M
+$51.33 (246.78%)
YTD
+$53.29 (282.86%)
1Y
+$57.46 (391.68%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
7 analysts · mean score 1.57
1 = Strong Buy · 5 = Sell
Strong Buy00%
Buy571%
Hold229%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$72.13
Average target$64.17
−$7.96 (−11.0%) downsideaverage target vs current price
CurrentAverageMedian
Low$46.00
Median$69.00
High$80.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-19 · Canaccord Genuity reiterated Buy on CDNA
Reiterated
2026-09-24 · BTIG reiterated Buy on CDNA
Initiated
2026-09-02 · Canaccord Genuity started covering CDNA at Buy
Reiterated
2026-08-06 · BTIG reiterated Buy on CDNA
Reiterated
2026-07-31 · HC Wainwright & Co. reiterated Neutral on CDNA
Reiterated
2026-07-16 · BTIG reiterated Buy on CDNA
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$3.6B
P/E (last 12 months)33.3
P/E (next 12 months, estimated)53.7
52-week range$14.22 – $72.71
Revenue growth (latest quarter vs a year ago)+52.2%
Dividend yieldNo dividend
Analyst consensusBuy (6)
Average analyst price target$64.17 (-11%)

What they do

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection.

Healthcare · Diagnostics & Research
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for CDNA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

CDNA earningsReports tomorrow
Next report · quarter Sep 2026
Thu Oct 29, 2026After the close
EPS consensus$0.26 range $0.24–$0.27
Revenue consensus$122.0M 7 analysts
Last 4 quarters · EPS vs estimate
Jul 30, 2026$0.37est $0.23+59.5%Above estimates
Apr 28, 2026$0.34est $0.13+161.5%Above estimates
Feb 24, 2026$0.12est $0.23−47.1%Below estimates
Nov 4, 2025$0.28est $0.14+97.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-25 07:25:27 ET
24-1125-0225-0425-0825-1126-0226-0426-070.000.37
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$131.9M+52.2%
2026-03-31$117.7M–
2025-12-31$108.4M–
2025-09-30$100.1M–
2025-06-30$86.7M–

News & catalysts

More news
CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026
Business Wire · Oct 22
CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026
Business Wire · Oct 15
CareDx (CDNA) Stock Gets Fair Value Bump After Reimbursement And Analyst Target Changes
Simply Wall St. · Oct 09
Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks
Zacks · Sep 30
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?
Zacks · Sep 25
Rating changes
Reiterated
2026-10-19 · Canaccord Genuity reiterated Buy on CDNA
Reiterated
2026-09-24 · BTIG reiterated Buy on CDNA
Initiated
2026-09-02 · Canaccord Genuity started covering CDNA at Buy
Reiterated
2026-08-06 · BTIG reiterated Buy on CDNA
Reiterated
2026-07-31 · HC Wainwright & Co. reiterated Neutral on CDNA
Reiterated
2026-07-16 · BTIG reiterated Buy on CDNA

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Novack Jeffrey Adam
Secretary and General Counsel · 2026-08-05
Sell
$23.4K
Novack Jeffrey Adam
Secretary and General Counsel · 2026-08-05
Sell
$101.0K
Bickerstaff George
Director · 2026-08-05
Sell
$925.7K
Goldberg Michael
Director · 2026-08-04
Sell
$2.1M
Cournoyer Christine
Director · 2026-08-04
Sell
$751.0K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-25 07:25:27 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026